Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 365,800 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
- Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 365,800 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
- The stock options were granted on August 17, 2022 at an exercise price of $2.15 per share, which is equal to the closing price of Geron common stock on the date of grant.
- The options were granted as material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of the stock option agreements covering the grants and Gerons 2018 Inducement Award Plan, which was adopted December 14, 2018 and provides for the granting of stock options to new employees.
- Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies.